<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39370123</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2093-2340</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Infection &amp; chemotherapy</Title><ISOAbbreviation>Infect Chemother</ISOAbbreviation></Journal><ArticleTitle>The Outcome of SARS-CoV-2 Infection in Patients with Lymphoma and the Risk Factors for the Development of Pneumonia.</ArticleTitle><Pagination><StartPage>378</StartPage><EndPage>385</EndPage><MedlinePgn>378-385</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3947/ic.2024.0046</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although patients with lymphoma appear particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the clinical evolution of coronavirus disease 2019 (COVID-19) in a patient with lymphoid malignancies has been under-represented, especially in relation to chemo-, chemo-immunotherapy.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Among adult patients with lymphoma receiving treatment in a specialized lymphoma center at a 500-bed, university-affiliated hospital, we retrospectively reviewed the medical records of patients diagnosed with SARS-CoV-2 infection from January 2020 to April 2022.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 117 patients with a median age of 53 years were included. One hundred twelves (95.7%) were non-Hodgkin lymphoma. Eighty-six patients (73.5%) were on active chemotherapy and 9 were post stem cell transplant state. Sixty-one patients had more than one comorbidity and 29 had hypogammaglobulinemia. Thirty-four patients (29.1%) had never received a COVID-19 vaccine. During a median follow-up of 134 days, COVID-19 pneumonia developed in 37 patients (31.6%). Excluding three patients who died before the 30 days, 31 out of 34 patients had ongoing symptomatic COVID-19. Eleven patients (9.4%) had post COVID-19 lung condition that persisted 90 days after COVID-19 diagnosis. Overall mortality was 10.3% (12 of 117), which was higher in patients with pneumonia. In multivariate analyses, age 65 years or older, follicular lymphoma, receiving rituximab maintenance therapy, and lack of vaccination were significantly associated with the development of COVID-19 pneumonia.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with lymphoma are at high risk for developing pneumonia after SARS-CoV-2 infection and suffer from prolonged symptoms. More aggressive vaccination and protective measures for patients with lymphoma who have impaired humoral response related to rituximab maintenance therapy and hypogammaglobulinemia are needed.</AbstractText><CopyrightInformation>© 2024 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, The Korean Society for AIDS, and Korean Society of Pediatric Infectious Diseases.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Hanter</ForeName><Initials>H</Initials><Identifier Source="ORCID">0009-0001-9593-8856</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Su-Mi</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-8187-5110</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. sumichoi@catholic.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Yeong-Woo</ForeName><Initials>YW</Initials><Identifier Source="ORCID">0000-0003-3362-8200</Identifier><AffiliationInfo><Affiliation>Division of Hematology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tong-Yoon</ForeName><Initials>TY</Initials><Identifier Source="ORCID">0000-0002-9559-992X</Identifier><AffiliationInfo><Affiliation>Division of Hematology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seohyun</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3248-7429</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Tai Joon</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0002-0286-2638</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Jeong Uk</ForeName><Initials>JU</Initials><Identifier Source="ORCID">0000-0001-8364-2380</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Chan Kwon</ForeName><Initials>CK</Initials><Identifier Source="ORCID">0000-0002-4107-444X</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022-1011-0003</GrantID><Agency>Yeouido St. Mary's hospital, Catholic University of Korea</Agency><Country>Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Infect Chemother</MedlineTA><NlmUniqueID>101531537</NlmUniqueID><ISSNLinking>1598-8112</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Lymphoma</Keyword><Keyword MajorTopicYN="N">Pneumonia</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>No conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39370123</ArticleId><ArticleId IdType="pmc">PMC11458498</ArticleId><ArticleId IdType="doi">10.3947/ic.2024.0046</ArticleId><ArticleId IdType="pii">56.378</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Park SS, Kim TY, Lee DG, Kim DW. Lymphopenia as a biological predictor of outcomes in COVID-19 patients: a nationwide cohort study. Cancers (Basel) 2021;13:471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7865511</ArticleId><ArticleId IdType="pubmed">33530509</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G, Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255743</ArticleId><ArticleId IdType="pubmed">32473681</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Verga L, Víšek B, Ilhan O, Nadali G, Weinbergerová B, Córdoba-Mascuñano R, Marchetti M, Collins GP, Farina F, Cattaneo C, Cabirta A, Gomes-Silva M, Itri F, van Doesum J, Ledoux MP, Čerňan M, Jakšić O, Duarte RF, Magliano G, Omrani AS, Fracchiolla NS, Kulasekararaj A, Valković T, Poulsen CB, Machado M, Glenthøj A, Stoma I, Ráčil Z, Piukovics K, Navrátil M, Emarah Z, Sili U, Maertens J, Blennow O, Bergantim R, García-Vidal C, Prezioso L, Guidetti A, Del Principe MI, Popova M, de Jonge N, Ormazabal-Vélez I, Fernández N, Falces-Romero I, Cuccaro A, Meers S, Buquicchio C, Antić D, Al-Khabori M, García-Sanz R, Biernat MM, Tisi MC, Sal E, Rahimli L, Čolović N, Schönlein M, Calbacho M, Tascini C, Miranda-Castillo C, Khanna N, Méndez GA, Petzer V, Novák J, Besson C, Duléry R, Lamure S, Nucci M, Zambrotta G, Žák P, Seval GC, Bonuomo V, Mayer J, López-García A, Sacchi MV, Booth S, Ciceri F, Oberti M, Salvini M, Izuzquiza M, Nunes-Rodrigues R, Ammatuna E, Obr A, Herbrecht R, Núñez-Martín-Buitrago L, Mancini V, Shwaylia H, Sciumè M, Essame J, Nygaard M, Batinić J, Gonzaga Y, Regalado-Artamendi I, Karlsson LK, Shapetska M, Hanakova M, El-Ashwah S, Borbényi Z, Çolak GM, Nordlander A, Dragonetti G, Maraglino AME, Rinaldi A, De Ramón-Sánchez C, Cornely OA. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) J Hematol Oncol. 2021;14:168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515781</ArticleId><ArticleId IdType="pubmed">34649563</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Tsukune Y, Watanabe N, Sugimoto K, Uchimura A, Tateyama M, Miyashita Y, Ochi Y, Komatsu N. Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20:774–776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7442568</ArticleId><ArticleId IdType="pubmed">32933879</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha Y, Wardle H, Evans AB, Hunter ER, Marr H, Osborne W, Bashton M, Smith D, Burton-Fanning S, Schmid ML, Duncan CJA. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. Ann Clin Microbiol Antimicrob. 2021;20:85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8717300</ArticleId><ArticleId IdType="pubmed">34969393</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima Y, Ogai A, Furukawa K, Arai R, Anan R, Nakano Y, Kurihara Y, Shimizu H, Misaki T, Okabe N. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother. 2021;27:387–389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836222</ArticleId><ArticleId IdType="pubmed">33328135</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi G, Rocchetti C, Magri R, Uccelli S, Bottone D, Quadri F, Novali M, Santin AD, Bezzi M. Hyperimmune plasma infusion in an immunocompromised Covid-19 patient previously treated for follicular lymphoma. Monaldi Arch Chest Dis. 2021;91:1867.</Citation><ArticleIdList><ArticleId IdType="pubmed">34121379</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarhini H, Recoing A, Bridier-Nahmias A, Rahi M, Lambert C, Martres P, Lucet JC, Rioux C, Bouzid D, Lebourgeois S, Descamps D, Yazdanpanah Y, Le Hingrat Q, Lescure FX, Visseaux B. Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection. J Infect Dis. 2021;223:1522–1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928754</ArticleId><ArticleId IdType="pubmed">33556961</ArticleId></ArticleIdList></Reference><Reference><Citation>Moran E, Cook T, Goodman AL, Gupta RK, Jolles S, Menon DK, Roberts DJ, Savic S, Shankar-Hari M, Brown M, Lowe DM. Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. Lancet Infect Dis. 2021;21:1345–1347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8367192</ArticleId><ArticleId IdType="pubmed">34411531</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Kim SE, Kim T, Yun KW, Lee SH, Lee E, Seo JW, Jung YH, Chong YP. Preliminary guidelines for the clinical evaluation and management of long COVID. Infect Chemother. 2022;54:566–597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9533168</ArticleId><ArticleId IdType="pubmed">36196612</ArticleId></ArticleIdList></Reference><Reference><Citation>National Evidence-based Healthcare Collaborating Agency (NECA); Korean Academy of Medical Sciences (KAMS) Korean COVID-19 living guideline.  [Accessed 1 May 2024].  Available at:  https://www.neca.re.kr/SKIN_DIR/doc.html?fn=f1f0928a-b101-432b-9802-a38c2c13db1c.pdf&amp;rs=/upload/synap/202405/</Citation></Reference><Reference><Citation>Bazdyrev E, Panova M, Zherebtsova V, Burdenkova A, Grishagin I, Novikov F, Nebolsin V. The hidden pandemic of COVID-19-induced organizing pneumonia. Pharmaceuticals (Basel) 2022;15:1574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9780828</ArticleId><ArticleId IdType="pubmed">36559025</ArticleId></ArticleIdList></Reference><Reference><Citation>Duléry R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T, Rossi C, Drenou B, Deau Fischer B, Soussain C, Feugier P, Noël N, Choquet S, Bologna S, Joly B, Philippe L, Kohn M, Malak S, Fouquet G, Daguindau E, Taoufik Y, Lacombe K, Cartron G, Thiéblemont C, Besson C. Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96:934–944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8212109</ArticleId><ArticleId IdType="pubmed">33909916</ArticleId></ArticleIdList></Reference><Reference><Citation>Assanto GM, Di Rocco A, Malfona F, Capriata M, Del Giudice I, Petrucci L, Girardi P, D'Elia GM, Martelli M, Gentile G, Micozzi A, Pulsoni A. Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study. Hematol Oncol. 2023;41:343–353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9877821</ArticleId><ArticleId IdType="pubmed">36521843</ArticleId></ArticleIdList></Reference><Reference><Citation>Chien KS, Peterson CB, Young E, Chihara D, Manasanch EE, Ramdial JL, Thompson PA. Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies. Blood Adv. 2023;7:5691–5697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9896882</ArticleId><ArticleId IdType="pubmed">36696472</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebers N, Speer C, Benning L, Bruch PM, Kraemer I, Meissner J, Schnitzler P, Kräusslich HG, Dreger P, Mueller-Tidow C, Poschke I, Dietrich S. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood. 2022;139:142–147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8530768</ArticleId><ArticleId IdType="pubmed">34669919</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martín-Moro F, Razanamahery J, Riches JC, Zwicker J, Patell R, Vekemans MC, Scarfò L, Chatzikonstantinou T, Yildiz H, Lattenist R, Mantzaris I, Wood WA, Hicks LK. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881–2892.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746126</ArticleId><ArticleId IdType="pubmed">33113551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong H, Choi SM, Kim TY, Jeon Yw, Kim S, An TJ, Lim JU, Park CK. Clinical characteristics and outcome of post COVID-19 lung conditions in patients with lymphoma. Infect Chemother. 2023;55(Suppl 2):S336.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>